Document is current
Any future updates will be listed below
-
Authors
Wang, Yun
Chen, Xiaoqin
Liang, Qi
Wang, Weida
Luo, Jun
Luo, Lin
Feng, Ru
Wei, Yongqiang
Tian, Yuyang
Du, Xin
Huang, Zhenqian
Hu, Guoyu
Fu, Xiangjun
Tao, Shi
Zhou, Jihao
Peng, Hongling
Su, Yongzhong
Zhang, Hongyu
Dong, Min
Lan, Mei
Sun, Zhiqiang
Wang, Xiuju
Zhou, Hui
Zhong, Liye
Peter Gale, Rober
Liang, Yang
Xia, Zhongjun
-
Funding
Funding for this research was provided by:
Beijing Xisike Clinical Oncology Research Foundation (Y-Young2022- -0281)
- License Information
-
More Information
Article History
Received: 9 September 2025
Accepted: 7 November 2025
First Online: 5 February 2026
Declarations
:
: This research was approved by the institutional review boards led by Sun Yat-sen University Cancer Center and was conducted in accordance with the Declaration of Helsinki. A waiver of informed consent was granted for anonymized data analysis.
: RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.
